Special delivery: Macromolecules via spider's 'bite'

May 24, 2017

Kyoto, Japan -- Our cells are rich in proteins which are potential targets for therapy. But study of these proteins' behavior, using externally delivered biomacromolecules, has often been stymied by the difficulty of gaining access to the interiors of living cells.

Now scientists at Kyoto University have used a reengineered spider venom peptide to deliver biomacromolecules - such as an antibody -- into a cell. Their strategy, appearing in Nature Chemistry, not only allows researchers to track the antibodies visually, but also makes it possible for the antibodies to interact with target proteins, modulating their functions.

"Efficient labeling of intracellular proteins with antibodies allows us to dramatically improve our understanding of their behavior and significance," explains first author Misao Akishiba. "Cells can take in antibodies through membrane-bound vesicles called 'endosomes'. But normally once inside these endosomes, the antibodies have trouble escaping."

The researchers found that a simple redesign of spider venom peptide 'M-lycotoxin' enables the efficient release of antibodies from their endosome cages.

"We took M-lycotoxin and replaced a leucine residue with glutamic acid, which we then called 'L17E'," continues Akishiba. "When L17E enters the cell, it specifically interacts with endosome membranes, breaking them down and releasing the antibodies."

The research team then showed that functional antibodies, such as those involved in suppressing gene expression, could be delivered as well.

"This will benefit not only basic science, but also the development of new treatments and drugs," concludes team leader Shiroh Futaki. "Moreover, this tool could potentially be used to transport other bioactive macromolecules -- and even nanoparticles -- into cells."

As a next step, the researchers hope to improve the efficiency of macromolecule uptake by endosomes, thereby increasing the amount of cargo that can be transported.
-end-
The paper "Cytosolic antibody delivery by lipid-sensitive endosomolytic peptide" appeared 22 May 2017 in the Nature Chemistry, with doi: 10.1038/nchem.2779

Kyoto University is one of Japan and Asia's premier research institutions, founded in 1897 and responsible for producing numerous Nobel laureates and winners of other prestigious international prizes. A broad curriculum across the arts and sciences at both undergraduate and graduate levels is complemented by numerous research centers, as well as facilities and offices around Japan and the world. For more information please see: http://www.kyoto-u.ac.jp/en

Kyoto University

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.